Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure
Completed
Conditions studied: Heart Failure, Dyspnea; Cardiac
In brief
Autophagy is considered an important component of Heart failure progression. Deubiquitination enzymes play an important role in autophagy. An important regulatory process within the autophagy pathway is ubiquitination. Ubiquitination targets proteins for degradation. On the contrary, de-ubiquitinating proteins (such as UCHL1) reverses this process. Studies have demonstrated deubiquitination to be linked to certain pathological processes, such as heart failure. UCHL1 will be examined as a potential marker of disease progression in acute decompensated heart failure.
Key facts
- Study ID
- NCT04999995
- Run by
- VA Office of Research and Development
- People needed
- 17
- Starts
- 2021-06-01
- Expected to finish
- 2025-03-17
- Last updated by the study team
- 2025-08-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Admission for decompensated HF (traditional diagnostic criteria will be utilized for diagnosing ADHF - presence of dyspnea as presenting complaint; evidence of volume overload - peripheral or pulmonary edema, elevated jugular venous pressure > 10 cmH2O, presence of hepatojugular reflux, or ascites; elevated B-type Natriuretic Peptide (>100ng/ml); evidence of pulmonary vascular congestion on chest x-ray1, or Admission for dyspnea that is NOT related to ADHF (absence of all HF symptoms and signs mentioned in ADHF inclusion criteria- except for dyspnea as presenting complaint)
- Able to give informed consent
- Age >= 18 years
You may not qualify if…
- Mortality during inpatient observation
- Presence of acute stroke (ischemic or hemorrhagic)
- Presence of intracranial hemorrhage
- History of acute stroke (ischemic or hemorrhagic) or intracranial hemorrhage within the preceding 6 months
- Presence of decompensated liver disease (elevated ALT/AST; ascites; Acute variceal bleeding; or hepatic encephalopathy)
- Presence of sepsis
- Presence of severe hyponatremia (Serum sodium < 130 meq/L)
- Active malignancy (undergoing chemotherapy, radiation therapy, or planned surgical intervention)
- SARS-CoV-2 positive during the current admission
Where it is running
- Wm. Jennings Bryan Dorn VA Medical Center, Columbia, SC — Columbia, South Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.